Cited by

• Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.

  Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP. Collins C, et al. Cancer Chemother Pharmacol. 1989;24(2):128-32. doi: 10.1007/BF00263134. Cancer Chemother Pharmacol. 1989. PMID: 2543513
• Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer.

  Figoli F, Veronesi A, Trovo MG, Errante D, Della Valentina M, Zagonel V, Talamini R, Magri MD, Monfardini S. Figoli F, et al. Cancer Chemother Pharmacol. 1989;24(6):381-5. doi: 10.1007/BF00257447. Cancer Chemother Pharmacol. 1989. PMID: 2551521
• A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer.

  Smit EF, Berendsen HH, de Vries EG, Mulder NH, Postmus PE. Smit EF, et al. Cancer Chemother Pharmacol. 1989;25(3):202-4. doi: 10.1007/BF00689583. Cancer Chemother Pharmacol. 1989. PMID: 2557171
• Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

  Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N. Sasaki Y, et al. Cancer Chemother Pharmacol. 1991;27(4):263-70. doi: 10.1007/BF00685110. Cancer Chemother Pharmacol. 1991. PMID: 1847845
• Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.

  Bishop JF, Kefford R, Raghavan D, Zalcberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K, et al. Bishop JF, et al. Cancer Chemother Pharmacol. 1990;25(5):367-70. doi: 10.1007/BF00686239. Cancer Chemother Pharmacol. 1990. PMID: 2155064